91´«Ã½ÔÚÏß

Research fundings.

Grant awards as main applicant:
Project: Development and preclinical assessment of RNA therapeutics targeting cFLIP-L splice variant to resensitize pancreatic cancer cells to treatment. Financing Firm/administration: Cancerforksningfonden. Main applicant: M Espona-Fiedler Duration: 2025-2028 Financial support: 200,000 SEK

Project: KRAS G12D synthetic lethality screening in mouse organoids: Identification of genetic vulnerabilities in pancreatic cancer. Financing Firm/administration: Cancerforksningfonden. Main applicant: M Espona-Fiedler. Co-applicant: Daniel Öhlund Duration: 2024-2027 Financial support: 150,000 SEK

Project: Targeting cFLIP to overcome gemcitabine resistance in pancreatic cancer. Financing Firm/administration: Cancerforksningfonden. Main applicant: M Espona-Fiedler. Co-applicant: Daniel Öhlund. Duration: 2022-2025 Financial support: 200,000 SEK

Grant awards as co-applicant:
Project: Characterization of pancreatic cancer subtypes and their impact on outcome through cell type-specific spatial transcriptomics. Financing Firm/administration: Cancerforksningfonden. Main applicant: Cedric Patthey. Co-applicant: M Espona-Fiedler Duration: 2024-2027 Financial support: 100,000 SEK

Other financial support:
Project: Targeting tumor-stroma interactions in pancreatic cancer. Financing Firm/administration: SciLifeLab Chemical Biology and Genome Engineering platform. PI and colls: Daniel Öhlund and Erik Chorell. Duration: 2021-2022 Financial support: 100,000 SEK

Complete list of publications.

Peer-reviewed original publications:
1.     Espona-Fiedler M, Manuel-Manresa P, Benitez-Garcia C, Fontova P, Quesada R, Soto-Cerrato V, Perez-Tomas R. Antimetastatic properties of Prodigiosin and the BH3-mimetic Obatoclax (GX15-070) in melanoma. Pharmaceutics. 2022 Dec 28;15(1):97. Impact factor: 6.5 (Scopus).

2.     Roberts JZ, Holohan C, Sessler T, Fox J, Crawford N, Riley JS, Khawaja H, Majkut J, Evergren E, Humphreys LM, Ferris J, Higgins C, Espona-Fiedler M, Moynagh P, McDade SS, Longley DB. The SCFSkp2 ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). Cell Death Differ. 2020 Sep;27(9):2726-2741. Impact factor: 10.7 (Scopus).

3.     Ferris J, Espona-Fiedler M, Hamilton C, Holohan C, Crawford N, McIntyre AJ, Roberts JZ, Wappett M, McDade SS, Longley DB, Coyle V. Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer. Cell Death Discov. 2020 Jul 21;6:61. Impact factor: 4.1 (Scopus).

4.     Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y, Mittal K, Kong B, Kurita T, Wei JJ. MED12 and HMGA2 alterations: Two independent genetic events in uterine leiomyoma and leiomyosarcoma. Modern Pathology (2014). 27; 8:1144-53. Impact factor: 5.2 (Scopus).

5.     Qiang W; Liu Z; Serna VA; Druschitz SA; Liu Y; Espona-Fiedler M; Wei JJ; Kurita T. Downregulation of miR-29b is essential for pathogenesis of uterine leiomyoma. Endocrinology (2014). 155; 3:633-9. Impact factor: 4.7 (Scopus).

6.     Hosseini A#; Espona-Fiedler M#; Soto-Cerrato V; Quesada R; Pérez-Tomás R; Guallar V. Molecular interactions of Prodiginines with the BH3 domain of antiapoptotic Bcl-2 family members. PLOS ONE (2013). 8; 2:e57562 (# equal contribution). Impact factor: 4.4 (Scopus).

7.     Espona-Fiedler M; Soto-Cerrato V; Hosseini A; Lizcano JM; Guallar V; Quesada R; Gao T; Pérez-Tomás R. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. Obatoclax. Biochemical Pharmacology (2012). 83; 4:489-496. Impact factor: 4.9 (Scopus).

8.     Díaz de Greñu B; Iglesias Hernández P; Espona-Fiedler M; Quiñonero D; Light ME; Torroba T; Pérez-Tomás R; Quesada R. Synthetic prodiginine obatoclax (GX15-070) and related analogues: anion binding, transmembrane transport, and cytotoxicity properties. Chemistry-A European Journal (2011). 17; 50:14074-14083. Impact factor: 5.5 (Scopus).

9.     Faiao-Flores F; Suarez JA; Soto-Cerrato V; Espona-Fiedler M; Perez-Tomas R; Maria DA. Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. Tumor Biology (2013). 34; 2:1235-1243. Impact factor: 3.61 (Scopus).

Manuscripts under peer-review in international journals:
1.     Mason J, Cumming J, Eriksson AU, Binder C, Dongre M, Patthey C, Espona-Fiedler M, Chorell E, Öhlund D. High throughput screen in a co-culture model to uncover therapeutic strategies to potentiate the cancer-inhibiting properties of the tumor-stroma in pancreatic cancer. https://www.biorxiv.org/content/10.1101/2022.03.11.483991v1 

Review articles:
1.     Espona-Fiedler M, Patthey C, Lindblad S, Öhlund D. Overcoming therapy resistance in pancreatic cancer: new insights and future directions. Biochem Pharm. 2024 Aug 15:229:116492. Impact factor: 5.8 (Scopus).

2.     Humphreys L#, Espona-Fiedler M#, Longley DB. FLIP as a therapeutic target in cancer. FEBS J. 2018 May 28 (# equal contribution). Impact factor: 4.5 (Scopus).

Conference papers:
1.     CA Higgins, J Majkut, L Humphreys, J Fox, M Espona-Fiedler, A Malik, Z Nemeth, P Blurton, RJ Boffey, TR Perrior, D Haigh, T Harrison, DB Longley. Development and pre-clinical assessment of a first-in-class small molecule inhibitor of FLIP for treatment of NSCLC and CRC. European Journal of Cancer; vol. 69, suppl. 1, pp S6 (2016).

2.     V Soto-Cerrato, M Espona-Fiedler, P Manuel-Manresa, C Garcia-Martinez, AM Rodilla, R Quesada, R Perez-Tomas. The antitumor agent obatoclax displays antimetastatic properties on melanoma cells in vitro and in vivo. European Journal of Cancer; vol 50, suppl 5, ppS207 (2014).

3.     M Espona-Fiedler, V Soto-Cerrato, A Husseini, V Guallar, R Perez-Tomas. Prodigiosin, a New Bcl-2 Homology Domain-3 Mimetic Proapoptotic Drug. European Journal of Cancer; vol 48, suppl 5, ppS239 (2012).

4.     C Garcia, M Toledo, M Espona-Fiedler, MP Aylwin, V Soto-Cerrato, F Penna, FJ Lopez-Soriano, JM Argiles, R Perez-Tomas, S Busquets. Prodigiosin increases ubiquitin-ligases gene expresión in human melanoma cell line SK-MEL-5. European Journal of Cancer; vol. 48, ppS243 (2012)

Teaching in Higher Education. 

2019 Fellow of Higher Education Academy (FHEA, UK)

2016-2018 Postgraduate certificate in Higher Education Teaching (PGCHET) - Queen´s University of Belfast

2008-2013 Assistant teacher in Cell Biology - Faculty of Medicine, Universitat de Barcelona

2007 Assistant teacher in Biochemistry - Faculty of Medicine, Universitat Autonoma de Barcelona